FDA Approval Insights: Daratumumab/Carfilzomib/Dexamethasone in Myeloma
Season 3, Episode 49, Oct 22, 2020, 06:50 PM
Today, we had the pleasure of speaking with Saad Z. Usmani, MD, FACP, of Atrium Health, to discuss the FDA approval of daratumumab in combination with carfilzomib and dexamethasone for patients with relapsed/refractory multiple myeloma who have received at least 1 prior line of therapy.